AU2009330686B2 - Compounds for the treatment of cancer - Google Patents

Compounds for the treatment of cancer Download PDF

Info

Publication number
AU2009330686B2
AU2009330686B2 AU2009330686A AU2009330686A AU2009330686B2 AU 2009330686 B2 AU2009330686 B2 AU 2009330686B2 AU 2009330686 A AU2009330686 A AU 2009330686A AU 2009330686 A AU2009330686 A AU 2009330686A AU 2009330686 B2 AU2009330686 B2 AU 2009330686B2
Authority
AU
Australia
Prior art keywords
methanone
trimethoxyphenyl
cancer
compound
thiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009330686A
Other languages
English (en)
Other versions
AU2009330686A1 (en
Inventor
Jianjun Chen
James T. Dalton
Chien-Ming Li
Wei Li
Yan Lu
Duane D. Miller
Zhao Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tennessee Research Foundation
Ohio State University Research Foundation
Original Assignee
University of Tennessee Research Foundation
Ohio State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tennessee Research Foundation, Ohio State University Research Foundation filed Critical University of Tennessee Research Foundation
Publication of AU2009330686A1 publication Critical patent/AU2009330686A1/en
Application granted granted Critical
Publication of AU2009330686B2 publication Critical patent/AU2009330686B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D263/06—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2009330686A 2008-06-16 2009-06-16 Compounds for the treatment of cancer Active AU2009330686B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6187508P 2008-06-16 2008-06-16
US61/061,875 2008-06-16
PCT/US2009/047572 WO2010074776A2 (en) 2008-06-16 2009-06-16 Compounds for the treatment of cancer

Publications (2)

Publication Number Publication Date
AU2009330686A1 AU2009330686A1 (en) 2010-07-01
AU2009330686B2 true AU2009330686B2 (en) 2014-07-03

Family

ID=41448223

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009330686A Active AU2009330686B2 (en) 2008-06-16 2009-06-16 Compounds for the treatment of cancer

Country Status (22)

Country Link
US (2) US8592465B2 (enExample)
EP (3) EP3289876B1 (enExample)
JP (2) JP5507552B2 (enExample)
KR (4) KR20170128623A (enExample)
CN (2) CN102137592B (enExample)
AU (1) AU2009330686B2 (enExample)
CA (2) CA2962524C (enExample)
CY (2) CY1119217T1 (enExample)
DK (3) DK2959900T3 (enExample)
ES (3) ES2715926T3 (enExample)
HR (1) HRP20221086T1 (enExample)
HU (3) HUE043569T2 (enExample)
IL (2) IL209995A (enExample)
LT (3) LT2303021T (enExample)
MX (1) MX2010014066A (enExample)
PL (3) PL2303021T3 (enExample)
PT (3) PT2303021T (enExample)
RU (1) RU2514427C2 (enExample)
SI (1) SI3289876T1 (enExample)
TR (1) TR201903981T4 (enExample)
UA (1) UA105005C2 (enExample)
WO (1) WO2010074776A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
DK2959900T3 (en) 2008-06-16 2017-06-26 Univ Tennessee Res Found CONNECTION TO TREATMENT OF CANCER
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
CN102883607B (zh) * 2010-03-01 2015-07-22 Gtx公司 用于治疗癌的化合物
AU2015227531B2 (en) * 2010-03-01 2017-03-02 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
CA3030689C (en) * 2010-08-24 2021-03-02 Gtx, Inc. Compounds for treatment of cancer
US8916555B2 (en) 2012-03-16 2014-12-23 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
EP2964028A4 (en) 2013-03-05 2017-06-07 University of Tennessee Research Foundation Compounds for treatment of cancer
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
SG10201704327RA (en) 2013-10-14 2017-06-29 Eisai R&D Man Co Ltd Selectively substituted quinoline compounds
MX363708B (es) 2013-10-14 2019-03-29 Eisai R&D Man Co Ltd Compuestos de quinolina selectivamente sustituidos.
WO2015115661A1 (ja) * 2014-02-03 2015-08-06 国立大学法人東京大学 アゾール誘導体骨格を有するペプチドの製造方法
ES2815374T3 (es) 2014-05-06 2021-03-29 Oncternal Therapeutics Inc Compuestos para el tratamiento del cáncer
ES2905280T3 (es) * 2014-07-03 2022-04-07 Celgene Quanticel Res Inc Inhibidores de la desmetilasa 1 específica de lisina
JP6450010B2 (ja) 2014-12-23 2019-01-09 アクシキン ファーマシューティカルズ インコーポレーテッド ３，５−ジアミノピラゾールキナーゼ阻害剤
RU2717238C2 (ru) 2015-03-30 2020-03-19 Мишн Терапьютикс Лимитед Соединения 1-циано-пирролидинов в качестве ингибиторов USP30
CN107840842A (zh) * 2016-09-19 2018-03-27 北京天诚医药科技有限公司 炔代杂环化合物、其制备方法及其在医药学上的应用
ES3008911T3 (en) 2017-07-11 2025-03-25 Vertex Pharma Carboxamides as modulators of sodium channels
TWI846350B (zh) 2017-09-15 2024-06-21 美商佛瑪治療公司 作為ＣＢＰ／ｐ３００抑制劑之四氫－咪唑並喹啉化合物
CN108586443B (zh) * 2018-01-31 2019-11-26 佳木斯大学附属第一医院 一种防治支气管肺癌的药物及其制备方法
WO2019188456A1 (ja) * 2018-03-26 2019-10-03 学校法人 川崎学園 新規抗腫瘍剤
EP3793549A4 (en) 2018-05-15 2022-03-09 University of Tennessee Research Foundation COMPOUNDS FOR THE TREATMENT OF TRIPLE NEGATIVE BREAST CANCER AND OVARIAN CANCER
AU2019270091A1 (en) * 2018-05-15 2020-12-24 University Of Tennessee Research Foundation Compounds for treatment of pancreatic cancer
MX2023013508A (es) 2018-06-29 2023-12-13 Forma Therapeutics Inc Inhibicion de la proteina de union a creb (cbp).
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
TW202102494A (zh) 2019-03-15 2021-01-16 美商弗瑪治療公司 抑制環amp-反應元件-結合蛋白(creb)
CR20220316A (es) 2019-12-06 2022-10-07 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
CN116745294A (zh) * 2020-12-25 2023-09-12 南京明德新药研发有限公司 酰胺噁唑类化合物
JP2024522292A (ja) 2021-06-04 2024-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルのモジュレーターとしてのｎ－（ヒドロキシアルキル（ヘテロ）アリール）テトラヒドロフランカルボキサミド
CN113999149B (zh) * 2021-11-15 2024-04-02 沈阳药科大学 一种基于l-半胱氨酸合成二芳基硫醚类化合物的制备方法
EP4504183A1 (en) * 2022-04-07 2025-02-12 Veru Inc. Methods of treating influenza and poxvirus viral infections
WO2024229440A2 (en) * 2023-05-03 2024-11-07 Emory University Methods of treating cancer using mdm2 inhibitors and compositions related thereto
CN119409641A (zh) * 2024-11-05 2025-02-11 杭州电子科技大学 一种磺酰基衍生物和用途

Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987132A (en) * 1987-02-20 1991-01-22 Yamanouchi Pharmaceutical Co., Ltd. Saturated heterocyclic carboxamide derivatives
EP0499987A1 (en) * 1991-02-20 1992-08-26 Abbott Laboratories Platelet activating factor antagonists
EP0549364A1 (en) * 1991-12-27 1993-06-30 Sankyo Company Limited Pyridylthiazolidinecarboxylic acid amide derivatives, their preparation and their therapeutic uses
US6080764A (en) * 1990-11-30 2000-06-27 Otsuka Pharmaceutical Co., Ltd. Superoxide radical inhibitor
WO2001017992A1 (en) * 1999-09-09 2001-03-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2002085899A1 (en) * 2001-04-19 2002-10-31 Vertex Pharmaceuticals Incorporated Heterocyclyldicarbamides as caspase inhibitors
WO2003037332A1 (en) * 2001-10-12 2003-05-08 Bayer Pharmaceuticals Corporation Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity
WO2003090680A2 (en) * 2002-04-23 2003-11-06 Axys Pharmaceuticals, Inc. Novel phenyl derivatives as inducers of apoptosis
US20040267017A1 (en) * 2001-09-26 2004-12-30 Bierer Donald E 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors
EP1535906A1 (en) * 2002-08-19 2005-06-01 Ono Pharmaceutical Co., Ltd. Nitrogen-containing compounds
WO2005086902A2 (en) * 2004-03-08 2005-09-22 Wyeth Ion channel modulators
US20060041006A1 (en) * 2004-05-06 2006-02-23 Ibrahim Prabha N PDE4B inhibitors and uses therefor
EP1637529A1 (en) * 2004-09-20 2006-03-22 4Sc Ag Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof
WO2006076706A1 (en) * 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
WO2006127587A1 (en) * 2005-05-20 2006-11-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
WO2007016979A2 (en) * 2005-07-29 2007-02-15 4Sc Ag NOVEL HETEROCYCLIC NF-κB INHIBITORS
WO2007058338A2 (en) * 2005-11-15 2007-05-24 Otsuka Pharmaceutical Co., Ltd. Oxazole compound and pharmaceutical composition
EP1832585A1 (en) * 2006-03-10 2007-09-12 ORIDIS BIOMED Forschungs- und Entwicklungs GmbH Thiazole-piperidine derivatives for treatment of hyperproliferative diseases
WO2007104558A1 (en) * 2006-03-15 2007-09-20 4Sc Ag Thiazoles as nf-kb inhibitors (proteasome inhibitors)
WO2007115805A2 (en) * 2006-04-05 2007-10-18 European Molecular Biology Laboratory (Embl) Aurora kinase inhibitors
WO2008006873A1 (en) * 2006-07-13 2008-01-17 Bayer Cropscience Sa Fungicide hydroximoyl-tetrazole derivatives
WO2008019357A2 (en) * 2006-08-07 2008-02-14 Ironwood Pharmaceuticals, Inc. Indole compounds
WO2008018426A1 (en) * 2006-08-08 2008-02-14 Chugai Seiyaku Kabushiki Kaisha Pyrimidine derivative as pi3k inhibitor and use thereof
WO2008023720A1 (en) * 2006-08-23 2008-02-28 Astellas Pharma Inc. Urea compound or salt thereof
WO2008030448A1 (en) * 2006-09-07 2008-03-13 Millennium Pharmaceuticals, Inc. Phenethylamide derivatives with kinase inhibitory activity
WO2008079277A1 (en) * 2006-12-22 2008-07-03 Millennium Pharmaceuticals, Inc. Certain pyrazoline derivatives with kinase inhibitory activity

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH528514A (de) 1969-05-22 1972-09-30 Bayer Ag Verfahren zur Herstellung von Acylimidazolen
US4721712A (en) 1984-06-12 1988-01-26 Pfizer Inc. 1,3-disubstituted 2-oxindoles as analgesic and anti-inflammatory agents
GB2287196B (en) 1991-09-30 1995-11-15 Philip Richardson A surgical incision member for use in suturing
JP3393891B2 (ja) 1992-08-18 2003-04-07 塩野義製薬株式会社 イミダゾール類の製造方法
US5514690A (en) 1992-11-17 1996-05-07 E. R. Squibb & Sons, Inc. Aminocarbonyl (thiocarbonyl) and cyanoguanidine derivatives of quinoline and indoline
JP2550915B2 (ja) 1994-06-21 1996-11-06 日本電気株式会社 印刷配線板の表面保護剤および表面保護膜の形成方法
ES2161916T3 (es) 1994-12-15 2001-12-16 Sankyo Co Derivados de la tiazolidinona o de la oxazolidinona para el tratamiento de la angina de pecho y composiciones que las contienen como ingrediente activo.
WO1996026931A1 (en) 1995-03-02 1996-09-06 Sankyo Company, Limited Optically active thiazolidinone derivatives
CA2294898A1 (en) 1997-07-03 1999-01-14 Neurogen Corporation Certain diarylimidazole derivatives; a new class of npy specific ligands
JP2004067510A (ja) 1997-12-26 2004-03-04 Mitsubishi Pharma Corp 新規イミダゾール誘導体
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
JP2001240593A (ja) * 1999-10-12 2001-09-04 Japan Tobacco Inc 高トリグリセリド血症治療薬及び抗肥満薬
ATE289293T1 (de) 1999-12-27 2005-03-15 Ortho Mcneil Pharm Inc Substituierte aminoalkylamid-derivate als antagonisten des follikel-stimulierenden hormons
MXPA02011079A (es) 2000-05-11 2004-08-19 Consejo Superior Investigacion Inhibidores heterociclicos de quinasa de sintasa de glucogeno gsk3.
ES2257461T3 (es) 2000-12-21 2006-08-01 Bristol-Myers Squibb Company Inhibidores de tiazolilo de tirosina quinasas de la familia tec.
WO2003016338A1 (en) 2001-08-15 2003-02-27 Parker Hughes Institute Crystal structure of the btk kinase domain
TWI231757B (en) * 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
UY27450A1 (es) * 2001-09-24 2003-04-30 Bayer Corp Preparación y uso de derivados de imidazol para el tratamiento de la obesidad
WO2003027105A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl thiophenes as c17,20 lyase inhibitors
FR2831536A1 (fr) 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
WO2003043998A1 (en) 2001-11-15 2003-05-30 Incyte San Diego Incorporated N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases
WO2003084940A1 (en) 2002-04-08 2003-10-16 Alangudi Sankaranarayanan Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
AU2003293376A1 (en) 2002-12-10 2004-06-30 Imclone Systems Incorporated Anti-angiogenic compounds and their use in cancer treatment
JP2006517234A (ja) 2003-02-10 2006-07-20 アムジエン・インコーポレーテツド バニロイド受容体リガンドおよび治療におけるこれらのリガンドの使用
EP1594847A2 (en) 2003-02-12 2005-11-16 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
RU2005134670A (ru) 2003-04-10 2006-06-10 Аванир Фармасьютикалс (Us) Производные имидазола для лечения аллергических и гиперпролиферативных нарушений
ATE363905T1 (de) 2003-04-17 2007-06-15 Janssen Pharmaceutica Nv 2-phenyl-benzimidazol und 2-phenyl-imidazo-4,5)- pyridin-derivate als checkpoint-kinase-cds1 (chk2)-hemmer zur behandlung von krebs
US20040248957A1 (en) 2003-05-16 2004-12-09 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
US6787245B1 (en) 2003-06-11 2004-09-07 E. I. Du Pont De Nemours And Company Sulfonated aliphatic-aromatic copolyesters and shaped articles produced therefrom
US7977387B2 (en) * 2003-07-24 2011-07-12 Leo Pharma A/S Aminobenzophenone compounds
WO2005014534A1 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
US20060014740A1 (en) 2003-11-18 2006-01-19 Miller Duane D Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof
WO2005049591A1 (en) 2003-11-18 2005-06-02 University Of Tennessee Research Foundation Thiazolidinone amides, thiazolidine carboxylic acid amides, methods of making, and uses thereof
AU2004298486A1 (en) 2003-12-12 2005-06-30 Wyeth Quinolines useful in treating cardiovascular disease
WO2005080367A1 (en) * 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
EP2298292A3 (en) 2004-06-18 2011-08-10 Agennix USA Inc. Kinase inhibitors for treating cancers
RU2383542C2 (ru) * 2004-08-17 2010-03-10 Ф.Хоффманн-Ля Рош Аг Замещенные гидантоины
US20060211603A1 (en) * 2004-08-18 2006-09-21 Vicuron Pharmaceuticals Inc. Ramoplanin derivatives possessing antibacterial activity
EP1627876A1 (en) 2004-08-20 2006-02-22 Ferring B.V. Heterocyclic condensed compounds useful as antidiuretic agents
WO2006063585A1 (en) 2004-12-13 2006-06-22 Leo Pharma A/S Triazole substituted aminobenzophenone compounds
CN101137412B (zh) 2005-01-13 2012-11-07 布里斯托尔-迈尔斯·斯奎布公司 用作凝血因子XIa抑制剂的取代的二芳基化合物
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
WO2008036067A2 (en) 2005-07-19 2008-03-27 The University Of Tennessee Research Foundation Thiazolidinone amides, thiazolidine carboxylic acid amides, and serine amides, including polyamine conjugates thereof, as selective anti-cancer agents
AU2006301222A1 (en) * 2005-10-14 2007-04-19 Neurosearch A/S Imidazole derivatives for the treatment of anxiety and related diseases
KR101081293B1 (ko) 2006-01-18 2011-11-08 에프. 호프만-라 로슈 아게 11 베타-에이치에스디1 억제제로서 티아졸
US7612212B2 (en) 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
WO2007146230A2 (en) 2006-06-14 2007-12-21 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
PE20080948A1 (es) 2006-07-25 2008-09-10 Irm Llc Derivados de imidazol como moduladores de la senda de hedgehog
KR100932093B1 (ko) * 2006-09-27 2009-12-16 주식회사종근당 미세소관 형성 저해제로서 유용한 벤조페논 유도체
WO2008128179A1 (en) 2007-04-14 2008-10-23 The University Of Tennessee Research Foundation Thiazolidinone amides, thiazolidine carboxylic acid amides, and serine amides, including polyamine conjugates thereof, as selective anti-cancer agents
US20090142832A1 (en) 2007-11-29 2009-06-04 James Dalton Indoles, Derivatives, and Analogs Thereof and Uses Therefor
WO2009076454A2 (en) 2007-12-12 2009-06-18 Calcimedica, Inc. Compounds that modulate intracellular calcium
DK2959900T3 (en) 2008-06-16 2017-06-26 Univ Tennessee Res Found CONNECTION TO TREATMENT OF CANCER
US9029408B2 (en) * 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
ES2745479T3 (es) 2009-10-16 2020-03-02 Novartis Ag Combinación que comprende un inhibidor de MEK y un inhibidor de B-raf
KR101134194B1 (ko) 2009-12-03 2012-04-09 서울대학교산학협력단 헤테로바이아릴피리딘 유도체 화합물의 제조방법 및 이러한 방법에 의해 제조된 헤테로바이아릴피리딘 유도체 화합물
CN102883607B (zh) 2010-03-01 2015-07-22 Gtx公司 用于治疗癌的化合物
US8426418B2 (en) 2010-08-27 2013-04-23 CollabRx Inc. Method to treat melanoma in BRAF inhibitor-resistant subjects
KR101418229B1 (ko) 2011-03-29 2014-07-09 미쓰비시덴키 가부시키가이샤 서보 제어 장치의 이상 진단 장치 및 이상 진단 시스템
WO2012135759A1 (en) 2011-04-01 2012-10-04 Genentech, Inc. Combinations of akt inhibitor compounds and abiraterone, and methods of use
PL2694510T3 (pl) 2011-04-07 2016-03-31 Bayer Ip Gmbh Imidazopirydazyny jako inhibitory kinazy Akt
EP2964028A4 (en) * 2013-03-05 2017-06-07 University of Tennessee Research Foundation Compounds for treatment of cancer

Patent Citations (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987132A (en) * 1987-02-20 1991-01-22 Yamanouchi Pharmaceutical Co., Ltd. Saturated heterocyclic carboxamide derivatives
US6080764A (en) * 1990-11-30 2000-06-27 Otsuka Pharmaceutical Co., Ltd. Superoxide radical inhibitor
EP0499987A1 (en) * 1991-02-20 1992-08-26 Abbott Laboratories Platelet activating factor antagonists
EP0549364A1 (en) * 1991-12-27 1993-06-30 Sankyo Company Limited Pyridylthiazolidinecarboxylic acid amide derivatives, their preparation and their therapeutic uses
WO2001017992A1 (en) * 1999-09-09 2001-03-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2002085899A1 (en) * 2001-04-19 2002-10-31 Vertex Pharmaceuticals Incorporated Heterocyclyldicarbamides as caspase inhibitors
US20040267017A1 (en) * 2001-09-26 2004-12-30 Bierer Donald E 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors
WO2003037332A1 (en) * 2001-10-12 2003-05-08 Bayer Pharmaceuticals Corporation Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity
WO2003090680A2 (en) * 2002-04-23 2003-11-06 Axys Pharmaceuticals, Inc. Novel phenyl derivatives as inducers of apoptosis
EP1535906A1 (en) * 2002-08-19 2005-06-01 Ono Pharmaceutical Co., Ltd. Nitrogen-containing compounds
WO2005086902A2 (en) * 2004-03-08 2005-09-22 Wyeth Ion channel modulators
US20060041006A1 (en) * 2004-05-06 2006-02-23 Ibrahim Prabha N PDE4B inhibitors and uses therefor
WO2006078287A2 (en) * 2004-05-06 2006-07-27 Plexxikon, Inc. Pde4b inhibitors and uses therefor
EP1637529A1 (en) * 2004-09-20 2006-03-22 4Sc Ag Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof
WO2006076706A1 (en) * 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
WO2006127587A1 (en) * 2005-05-20 2006-11-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
WO2007016979A2 (en) * 2005-07-29 2007-02-15 4Sc Ag NOVEL HETEROCYCLIC NF-κB INHIBITORS
WO2007058338A2 (en) * 2005-11-15 2007-05-24 Otsuka Pharmaceutical Co., Ltd. Oxazole compound and pharmaceutical composition
EP1832585A1 (en) * 2006-03-10 2007-09-12 ORIDIS BIOMED Forschungs- und Entwicklungs GmbH Thiazole-piperidine derivatives for treatment of hyperproliferative diseases
WO2007104558A1 (en) * 2006-03-15 2007-09-20 4Sc Ag Thiazoles as nf-kb inhibitors (proteasome inhibitors)
WO2007115805A2 (en) * 2006-04-05 2007-10-18 European Molecular Biology Laboratory (Embl) Aurora kinase inhibitors
WO2008006873A1 (en) * 2006-07-13 2008-01-17 Bayer Cropscience Sa Fungicide hydroximoyl-tetrazole derivatives
WO2008019357A2 (en) * 2006-08-07 2008-02-14 Ironwood Pharmaceuticals, Inc. Indole compounds
WO2008018426A1 (en) * 2006-08-08 2008-02-14 Chugai Seiyaku Kabushiki Kaisha Pyrimidine derivative as pi3k inhibitor and use thereof
WO2008023720A1 (en) * 2006-08-23 2008-02-28 Astellas Pharma Inc. Urea compound or salt thereof
WO2008030448A1 (en) * 2006-09-07 2008-03-13 Millennium Pharmaceuticals, Inc. Phenethylamide derivatives with kinase inhibitory activity
WO2008079277A1 (en) * 2006-12-22 2008-07-03 Millennium Pharmaceuticals, Inc. Certain pyrazoline derivatives with kinase inhibitory activity

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Giordano, C. et al, "New Strategy for Racemization of 2-Amino-1,3-propanediols, Key Intermediates for the Synthesis of Antibiotic Drugs", Tetrahedron Letters, 1988, vol. 29(43), pp. 5561- 5564 *
Mahboobi, S. et al, "Synthesis of Naturally Occurring Pyrazine and Imidazole Alkaloids from Botryllus Leachi", Monatshefte fur Chemie, 2004, vol. 135, pp. 333-342 *
Sheppard, G.S. et al, "3-(2-(3-Pyridinyl)thiazolidin-4-oyl)indoles, a Novel Series of Platelet Activating Factor Antagonists", Journal of Medicinal Chemistry, 1994, vol. 37, pp. 2011-2032 *
Terasawa, K. et al, "Cytotoxic Activity of Benzoylimidazole and Related Compounds against Human Oral Tumor Cell Lines", Anticancer Research, 2001, vol. 21, pp. 1081-1086 *
Tucker, J.A. et al, "Structure-Activity Relationships of Acyloxyamidine Cytomegalovirus DNA Polymerase Inhibitors", Bioorganic & Medicinal Chemistry, 2000, vol. 8, pp. 601-615 *

Also Published As

Publication number Publication date
EP2303021B1 (en) 2018-12-19
RU2010154172A (ru) 2012-07-27
PL2959900T3 (pl) 2017-11-30
CA2728118C (en) 2018-01-16
US20190092755A1 (en) 2019-03-28
EP3289876B1 (en) 2022-07-20
KR20170128623A (ko) 2017-11-22
EP3289876A1 (en) 2018-03-07
DK2959900T3 (en) 2017-06-26
CY1119217T1 (el) 2018-02-14
DK2303021T3 (en) 2019-04-08
LT3289876T (lt) 2022-11-10
HUE043569T2 (hu) 2019-08-28
EP2959900A1 (en) 2015-12-30
HRP20221086T1 (hr) 2022-11-25
ES2715926T3 (es) 2019-06-07
ES2629927T3 (es) 2017-08-16
SI3289876T1 (sl) 2023-01-31
LT2959900T (lt) 2017-09-25
DK3289876T3 (da) 2022-10-10
CA2728118A1 (en) 2010-07-01
KR102025213B1 (ko) 2019-09-25
PT2959900T (pt) 2017-06-22
US20090326020A1 (en) 2009-12-31
KR20110022672A (ko) 2011-03-07
TR201903981T4 (tr) 2019-04-22
AU2009330686A1 (en) 2010-07-01
IL229878A0 (en) 2014-01-30
PT3289876T (pt) 2022-10-28
CN104610230A (zh) 2015-05-13
CN102137592B (zh) 2015-01-28
PT2303021T (pt) 2019-04-01
CY1121724T1 (el) 2020-07-31
MX2010014066A (es) 2011-06-01
KR20170029031A (ko) 2017-03-14
CN102137592A (zh) 2011-07-27
CA2962524A1 (en) 2010-07-01
JP2012162541A (ja) 2012-08-30
HUE060249T2 (hu) 2023-02-28
CA2962524C (en) 2020-07-14
JP5507552B2 (ja) 2014-05-28
EP2959900B1 (en) 2017-03-08
EP2303021A2 (en) 2011-04-06
UA105005C2 (uk) 2014-04-10
WO2010074776A2 (en) 2010-07-01
RU2514427C2 (ru) 2014-04-27
IL229878A (en) 2015-04-30
US10865196B2 (en) 2020-12-15
JP2011524422A (ja) 2011-09-01
EP2303021A4 (en) 2012-03-14
ES2927660T3 (es) 2022-11-10
PL2303021T3 (pl) 2019-10-31
PL2959900T4 (pl) 2017-11-30
PL3289876T3 (pl) 2022-11-21
LT2303021T (lt) 2019-06-25
US8592465B2 (en) 2013-11-26
IL209995A (en) 2014-05-28
WO2010074776A3 (en) 2010-08-19
KR20160079934A (ko) 2016-07-06
HUE034598T2 (en) 2018-02-28
IL209995A0 (en) 2011-02-28

Similar Documents

Publication Publication Date Title
AU2009330686B2 (en) Compounds for the treatment of cancer
US9029408B2 (en) Compounds for treatment of cancer
EP2178870A1 (en) Indole and indazole compounds as an inhibitor of cellular necrosis
US20060014740A1 (en) Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof
US20080255213A1 (en) Thiazolidinone amides, thiazolidine carboxylic acid amides, and serine amides, including polyamine conjugates thereof, as selective anti-cancer agents
HK1156189B (en) Compounds for the treatment of cancer
HK1156189A (en) Compounds for the treatment of cancer
AU2005220705A1 (en) Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)